系统免疫调节疗法治中毒性表皮坏死松解症:系统评价与网状Meta分析
该系统评价与网状Meta分析纳入67项研究共2079例SJS/TEN重叠或TEN患者,评估系统免疫调节治疗对死亡率的影响。网状Meta分析显示,10种治疗中无一优于支持治疗,沙利度胺与死亡率显著升高相关(OR 11.67,95%CI 1.42-95.96);基于SCORTEN的标准化死亡比分析中,仅糖皮质激素联合IVIg显示显著生存获益(SMR 0.53,95%CI 0.31-0.93)。
要点
- 糖皮质激素联合IVIg可能是唯一显著降低SJS/TEN重叠和TEN死亡风险的治疗。
- 沙利度胺与死亡率显著升高相关,不应使用。
- 环孢素和依那西普前景可期,但证据尚不充分。
核心结论
- 糖皮质激素联合IVIg可能降低SJS/TEN重叠和TEN患者的死亡风险。
- 环孢素和依那西普是有前景的治疗,但需更多研究提供更明确证据。
研究设计与样本
- 系统评价与网状Meta分析,检索在线数据库(自建库至2019年10月31日)。
- 纳入67项研究,共2079例SJS/TEN重叠或TEN患者。
- 采用频率随机效应模型进行网状Meta分析。
主要发现
- 10种治疗的网状Meta分析显示,无一优于支持治疗降低死亡率。
- 沙利度胺与死亡率显著升高相关(OR 11.67,95%CI 1.42-95.96)。
- 11个治疗臂的网状Meta分析显示,糖皮质激素联合IVIg是唯一有显著生存获益的治疗(SMR 0.53,95%CI 0.31-0.93)。
关键数值与推荐
- 主要结局为死亡率和基于SCORTEN的标准化死亡比(SMR)。
- 沙利度胺的OR为11.67(95%CI 1.42-95.96)。
- 糖皮质激素联合IVIg的SMR为0.53(95%CI 0.31-0.93)。
临床怎么用
- 对于SJS/TEN重叠和TEN患者,可考虑糖皮质激素联合IVIg以降低死亡风险。
- 避免使用沙利度胺治疗TEN。
- 环孢素和依那西普可作为潜在选择,但需个体化评估并关注新证据。
局限性
- 研究间存在异质性。
- 符合条件的随机对照试验数量不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various systemic immunomodulating therapies have been used to treat toxic epidermal necrolysis (TEN), but their efficacy remains unclear. OBJECTIVE: To perform a systematic review and network meta-analysis (NMA) evaluating the effects of systemic immunomodulating therapies on mortality for Stevens-Johnson syndrome (SJS)/TEN overlap and TEN. METHODS: A literature search was performed in online databases (from inception to October 31, 2019). Outcomes were mortality rates and Score of Toxic Epidermal Necrolysis (SCORTEN)-based standardized mortality ratio (SMR). A frequentist random-effects model was adopted. RESULTS: Sixty-seven studies involving 2079 patients were included. An NMA of 10 treatments showed that none was superior to supportive care in reducing mortality rates and that thalidomide was associated with a significantly higher mortality rate (odds ratio, 11.67; 95% confidence interval [CI], 1.42-95.96). For SMR, an NMA of 11 treatment arms showed that corticosteroids and intravenous immunoglobulin combination therapy was the only treatment with significant survival benefits (SMR, 0.53; 95% CI, 0.31-0.93). LIMITATIONS: Heterogeneity and a paucity of eligible randomized controlled trials. CONCLUSIONS: Combination therapy with corticosteroids and IVIg may reduce mortality risks in patients with SJS/TEN overlap and TEN. Cyclosporine and etanercept are promising therapies, but more studies are required to provide clearer evidence.
引用
- Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. J Am Acad Dermatol. 2020. PMID: 32898587. doi:10.1016/j.jaad.2020.08.122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。